97 related articles for article (PubMed ID: 17884497)
1. The discovery of substituted 4-(3-hydroxyanilino)-quinolines as potent RET kinase inhibitors.
Graham Robinett R; Freemerman AJ; Skinner MA; Shewchuk L; Lackey K
Bioorg Med Chem Lett; 2007 Nov; 17(21):5886-93. PubMed ID: 17884497
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold.
Brandt W; Mologni L; Preu L; Lemcke T; Gambacorti-Passerini C; Kunick C
Eur J Med Chem; 2010 Jul; 45(7):2919-27. PubMed ID: 20409618
[TBL] [Abstract][Full Text] [Related]
3. Identification and structure-activity relationship of 8-hydroxy-quinoline-7-carboxylic acid derivatives as inhibitors of Pim-1 kinase.
Sliman F; Blairvacq M; Durieu E; Meijer L; Rodrigo J; Desmaƫle D
Bioorg Med Chem Lett; 2010 May; 20(9):2801-5. PubMed ID: 20363627
[TBL] [Abstract][Full Text] [Related]
4. Pharmacophore modeling and virtual screening to identify potential RET kinase inhibitors.
Shih KC; Shiau CW; Chen TS; Ko CH; Lin CL; Lin CY; Hwang CS; Tang CY; Chen WR; Huang JW
Bioorg Med Chem Lett; 2011 Aug; 21(15):4490-7. PubMed ID: 21724393
[TBL] [Abstract][Full Text] [Related]
5. Targeting RET for thyroid cancer therapy.
Lanzi C; Cassinelli G; Nicolini V; Zunino F
Biochem Pharmacol; 2009 Feb; 77(3):297-309. PubMed ID: 19028457
[TBL] [Abstract][Full Text] [Related]
6. Structural modification of an EGFR inhibitor that showed weak off-target activity against RET leading to the discovery of a potent RET inhibitor.
Sun QZ; Xu Y; Liu JJ; Zhang CH; Wang ZR; Zheng RL; Wang WJ; Li LL; Yang SY
Mol Divers; 2014 May; 18(2):403-9. PubMed ID: 24515340
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, modeling, and RET protein kinase inhibitory activity of 3- and 4-substituted beta-carbolin-1-ones.
Cincinelli R; Cassinelli G; Dallavalle S; Lanzi C; Merlini L; Botta M; Tuccinardi T; Martinelli A; Penco S; Zunino F
J Med Chem; 2008 Dec; 51(24):7777-87. PubMed ID: 19053769
[TBL] [Abstract][Full Text] [Related]
8. Targeting RET receptor tyrosine kinase activation in cancer.
Phay JE; Shah MH
Clin Cancer Res; 2010 Dec; 16(24):5936-41. PubMed ID: 20930041
[TBL] [Abstract][Full Text] [Related]
9. 4-Anilino-7,8-dialkoxybenzo[g]quinoline-3-carbonitriles as potent Src kinase inhibitors.
Berger DM; Dutia M; Birnberg G; Powell D; Boschelli DH; Wang YD; Ravi M; Yaczko D; Golas J; Lucas J; Boschelli F
J Med Chem; 2005 Sep; 48(19):5909-20. PubMed ID: 16161995
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of RET tyrosine kinase by SU5416.
Mologni L; Sala E; Cazzaniga S; Rostagno R; Kuoni T; Puttini M; Bain J; Cleris L; Redaelli S; Riva B; Formelli F; Scapozza L; Gambacorti-Passerini C
J Mol Endocrinol; 2006 Oct; 37(2):199-212. PubMed ID: 17032739
[TBL] [Abstract][Full Text] [Related]
11. Optimization of 7-alkene-3-quinolinecarbonitriles as Src kinase inhibitors.
Boschelli DH; Wang D; Wang Y; Wu B; Honores EE; Barrios Sosa AC; Chaudhary I; Golas J; Lucas J; Boschelli F
Bioorg Med Chem Lett; 2010 May; 20(9):2924-7. PubMed ID: 20363128
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent.
Wang Y; Ai J; Wang Y; Chen Y; Wang L; Liu G; Geng M; Zhang A
J Med Chem; 2011 Apr; 54(7):2127-42. PubMed ID: 21405128
[TBL] [Abstract][Full Text] [Related]
13. Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma.
Santarpia L; Ye L; Gagel RF
J Intern Med; 2009 Jul; 266(1):99-113. PubMed ID: 19522829
[TBL] [Abstract][Full Text] [Related]
14. The design, synthesis and biological evaluation of 7-alkoxy-4-heteroarylamino-3-cyanoquinolines as dual inhibitors of c-Src and iNOS.
Cao X; You QD; Li ZY; Liu XR; Xu D; Guo QL; Shang J; Chern JW; Chen ML
Bioorg Med Chem Lett; 2008 Dec; 18(23):6206-9. PubMed ID: 18930653
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor.
Yoon H; Shin I; Nam Y; Kim ND; Lee KB; Sim T
Eur J Med Chem; 2017 Jan; 125():1145-1155. PubMed ID: 27814560
[TBL] [Abstract][Full Text] [Related]
16. 4-Anilino-7-pyridyl-3-quinolinecarbonitriles as Src kinase inhibitors.
Zhang N; Wu B; Boschelli DH; Golas JM; Boschelli F
Bioorg Med Chem Lett; 2009 Sep; 19(17):5071-4. PubMed ID: 19632113
[TBL] [Abstract][Full Text] [Related]
17. Discovery of
Mologni L; Dalla Via M; Chilin A; Palumbo M; Marzaro G
ChemMedChem; 2017 Aug; 12(16):1390-1398. PubMed ID: 28639308
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 4-chloro-3-(5-(pyridin-3-yl)-1,2,4-oxadiazole-3-yl)benzamides as novel RET kinase inhibitors.
Han M; Li S; Ai J; Sheng R; Hu Y; Hu Y; Geng M
Bioorg Med Chem Lett; 2016 Dec; 26(23):5679-5684. PubMed ID: 27815117
[TBL] [Abstract][Full Text] [Related]
19. Structure activity relationships of quinoline-containing c-Met inhibitors.
Kung PP; Funk L; Meng J; Alton G; Padrique E; Mroczkowski B
Eur J Med Chem; 2008 Jun; 43(6):1321-9. PubMed ID: 17964000
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor.
Pawar VG; Sos ML; Rode HB; Rabiller M; Heynck S; van Otterlo WA; Thomas RK; Rauh D
J Med Chem; 2010 Apr; 53(7):2892-901. PubMed ID: 20222733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]